Published in Front Neurol on March 13, 2017
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
Alzheimer's disease is a synaptic failure. Science (2002) 13.82
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol (2010) 11.19
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A (1998) 8.41
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol (2006) 8.15
Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology (2002) 7.73
alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol (2002) 6.64
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A (2000) 5.83
Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci (2001) 5.32
The molecular mechanics of eukaryotic translation. Annu Rev Biochem (2004) 5.21
Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci (2001) 4.92
Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron (2010) 4.76
Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem (2006) 4.06
Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A (2000) 3.86
The roles of ribosomal proteins in the structure assembly, and evolution of the large ribosomal subunit. J Mol Biol (2004) 3.73
The nucleolus under stress. Mol Cell (2010) 3.63
Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim Biophys Acta (2008) 3.51
Driving ribosome assembly. Biochim Biophys Acta (2009) 3.14
False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies. J Clin Epidemiol (2014) 3.04
Neuroinflammation in Alzheimer's disease. Lancet Neurol (2015) 3.02
Rapidly progressive dementia. Ann Neurol (2008) 3.00
Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci (2007) 2.96
Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol (2002) 2.92
Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol (1998) 2.73
Ribosome biogenesis: of knobs and RNA processing. Exp Cell Res (2004) 2.70
Dementia with Lewy bodies. Lancet Neurol (2004) 2.66
Microglia: biology and pathology. Acta Neuropathol (2009) 2.51
Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A (2005) 2.45
Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci (2015) 2.25
Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology (2009) 2.23
Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol (2005) 2.21
Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. Nat Protoc (2012) 2.12
Sensing cellular stress: another new function for the nucleolus? Sci STKE (2004) 2.09
Cortical inflammation in Alzheimer disease but not dementia with Lewy bodies. Arch Neurol (2000) 2.08
A review: inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal (2012) 2.03
Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging (2001) 1.89
A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci (2010) 1.80
The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol (2010) 1.80
Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing. Int J Mol Sci (2009) 1.67
Neuroinflammation - an early event in both the history and pathogenesis of Alzheimer's disease. Neurodegener Dis (2010) 1.66
Structural basis of the translational elongation cycle. Annu Rev Biochem (2013) 1.65
Adenosine as a neuromodulator in neurological diseases. Curr Opin Pharmacol (2007) 1.61
Inflammation and Alzheimer's disease. Arch Pharm Res (2010) 1.60
Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol (2002) 1.59
Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology (2006) 1.57
Rapidly progressive diffuse Lewy body disease. Mov Disord (2011) 1.52
Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol (2008) 1.52
Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem (2003) 1.47
Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol (2008) 1.46
Rapidly progressive neurodegenerative dementias. Arch Neurol (2009) 1.46
Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol (2008) 1.45
Ectonucleotidases in the nervous system. Novartis Found Symp (2006) 1.40
SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain (2010) 1.38
Effects of antemortem and postmortem variables on human brain mRNA quality: a BrainNet Europe study. J Neuropathol Exp Neurol (2010) 1.36
Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol (2010) 1.34
Physical interaction between aldolase and vacuolar H+-ATPase is essential for the assembly and activity of the proton pump. J Biol Chem (2007) 1.25
The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol (2013) 1.23
Emerging roles of the neuronal nucleolus. Trends Neurosci (2012) 1.18
Cycles of aberrant synaptic sprouting and neurodegeneration in Alzheimer's and dementia with Lewy bodies. Neurochem Res (2003) 1.18
Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol (2009) 1.17
TaqMan PCR assay in the control of RNA normalization in human post-mortem brain tissue. Neurochem Int (2006) 1.15
Dynamics of nucleotide metabolism as a supporter of life phenomena. J Med Invest (2005) 1.15
Physiological and pathological properties of alpha-synuclein. Cell Mol Life Sci (2007) 1.14
The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med (2009) 1.13
Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol (2015) 1.11
Adenosine and ATP receptors in the brain. Curr Top Med Chem (2011) 1.10
Nme protein family evolutionary history, a vertebrate perspective. BMC Evol Biol (2009) 1.09
Microglia actions in Alzheimer’s disease. Acta Neuropathol (2013) 1.09
Structural basis for substrate specificities of cellular deoxyribonucleoside kinases. Nat Struct Biol (2001) 1.07
Amyloid β-protein oligomers and Alzheimer's disease. Alzheimers Res Ther (2013) 1.07
Brain banks: benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies. Cell Tissue Bank (2008) 1.06
Rapidly progressive Alzheimer's disease features distinct structures of amyloid-β. Brain (2015) 1.04
Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies. Free Radic Biol Med (2009) 1.03
Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochem Pharmacol (2014) 1.01
Chemokines and Alzheimer's disease. Neurobiol Aging (2001) 1.00
Mitochondrial ATP-synthase in the entorhinal cortex is a target of oxidative stress at stages I/II of Alzheimer's disease pathology. Brain Pathol (2009) 0.99
Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer's disease and dementia with Lewy bodies correlates with stage of Alzheimer's-disease-related changes. Neurobiol Dis (2005) 0.98
Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment. Autophagy (2014) 0.96
Nucleolar activity in neurodegenerative diseases: a missing piece of the puzzle? J Mol Med (Berl) (2012) 0.96
Autophagy in dementias. Brain Pathol (2012) 0.95
Nucleolar disruption and cajal body disassembly are nuclear hallmarks of DNA damage-induced neurodegeneration in purkinje cells. Brain Pathol (2010) 0.94
Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease. Acta Neuropathol (2014) 0.94
The Role of alpha-synuclein assembly and metabolism in the pathogenesis of Lewy body disease. J Mol Neurosci (2004) 0.93
Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol (2013) 0.92
Pathophysiology of synuclein aggregation in Lewy body disease. Mech Ageing Dev (2005) 0.91
Abnormal alpha-synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease. Neurobiol Dis (2004) 0.91
Neuroinflammatory signals in Alzheimer disease and APP/PS1 transgenic mice: correlations with plaques, tangles, and oligomeric species. J Neuropathol Exp Neurol (2015) 0.90
Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study. Acta Neuropathol (2012) 0.90
Expression profiles of cytokines in the brains of Alzheimer's disease (AD) patients compared to the brains of non-demented patients with and without increasing AD pathology. J Alzheimers Dis (2011) 0.90
Alteration of autophagosomal proteins (LC3, GABARAP and GATE-16) in Lewy body disease. Neurobiol Dis (2011) 0.90
Human brain nucleoside diphosphate kinase activity is decreased in Alzheimer's disease and Down syndrome. Biochem Biophys Res Commun (2002) 0.89
Oxidative damage to proteins, lipids, and DNA in cortical brain regions from patients with dementia with Lewy bodies. J Neurochem (1998) 0.89
Function of taurine transporter (Slc6a6/TauT) as a GABA transporting protein and its relevance to GABA transport in rat retinal capillary endothelial cells. Biochim Biophys Acta (2008) 0.89
Significance of brain lesions in Parkinson disease dementia and Lewy body dementia. Front Neurol Neurosci (2009) 0.88